Sign up to save your podcasts
Or
Share Stephen V. Liu, MD - A New Era Has Begun in the Treatment of SCLC: Navigating Novel Therapeutic Options and Strategies for Improving Patient Outcomes
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Stephen V. Liu, MD - A New Era Has Begun in the Treatment of SCLC: Navigating Novel Therapeutic Options and Strategies for Improving Patient Outcomes
Go online to PeerView.com/UXH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in oncology discuss various treatment options for small cell lung cancer (SCLC), including the rationale for using new therapies, key clinical trial data, and methods for integrating novel therapies into routine practice or through clinical trial participation. Upon completion of this activity, participants will be able to: Describe the mechanisms of action and rationale for use of novel therapies for SCLC, including immune checkpoint inhibitors, PARP inhibitors, transcription inhibitors, and other investigational agents and combinations, Discuss key clinical trials assessing different new therapies for SCLC, Evaluate the latest available clinical trial data regarding standard as well as novel/emerging therapeutic approaches for SCLC, Integrate novel therapies into treatment plans for patients with SCLC either in the context of routine clinical practice or clinical trial participation.
View all episodes
By PVI, PeerView Institute for Medical Education
5
33 ratings
Go online to PeerView.com/UXH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in oncology discuss various treatment options for small cell lung cancer (SCLC), including the rationale for using new therapies, key clinical trial data, and methods for integrating novel therapies into routine practice or through clinical trial participation. Upon completion of this activity, participants will be able to: Describe the mechanisms of action and rationale for use of novel therapies for SCLC, including immune checkpoint inhibitors, PARP inhibitors, transcription inhibitors, and other investigational agents and combinations, Discuss key clinical trials assessing different new therapies for SCLC, Evaluate the latest available clinical trial data regarding standard as well as novel/emerging therapeutic approaches for SCLC, Integrate novel therapies into treatment plans for patients with SCLC either in the context of routine clinical practice or clinical trial participation.
More shows like PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
View all
PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
3 Listeners
PeerView Gastroenterology CME/CNE/CPE Audio Podcast
3 Listeners
PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast
11 Listeners
PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
28 Listeners
PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
9 Listeners
PeerView Gastroenterology CME/CNE/CPE Video Podcast
3 Listeners
PeerView Internal Medicine CME/CNE/CPE Video Podcast
2 Listeners
PeerView Neuroscience & Psychiatry CME/CNE/CPE Video Podcast
4 Listeners
PeerView Endocrinology & Diabetes CME/CNE/CPE Video Podcast
3 Listeners
PeerView Infectious Diseases CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
2 Listeners
PeerView Infectious Diseases CME/CNE/CPE Video Podcast
0 Listeners
PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
9 Listeners
PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast
2 Listeners
PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
11 Listeners
PeerView Clinical Pharmacology CME/CNE/CPE Video
2 Listeners